Optune
Payments companies reported to CMS as associated with Optune. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Optune, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Optune
These are the largest totals companies reported as associated with Optune. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Samuel Goldlust | Kansas City, MO | Neurology (Psychiatry & Neurology) | $40,536.81 |
| Jennifer Serventi | Rochester, NY | Physician Assistant | $39,780.65 |
| Rimas Lukas | Chicago, IL | Hematology & Oncology | $32,497.34 |
| Nicholas Metrus | Summit, NJ | Neurology (Psychiatry & Neurology) | $31,329.14 |
| David Tran | Los Angeles, CA | Medical Oncology | $28,242.73 |
| Ramji Rajendran | Elk Grove Village, IL | Radiation Oncology | $27,264.61 |
| Alexander Whitley | Montgomery, AL | Radiation Oncology | $26,876.49 |
| Amir Lavaf | Palm Springs, CA | Radiation Oncology | $26,495.09 |
| Suriya Jeyapalan | Boston, MA | Neurology (Psychiatry & Neurology) | $24,929.30 |
| Paul Derose | Richardson, TX | Radiation Oncology | $23,043.20 |
Prescribed Optune?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.